by Tara Fernandez | Jul 7, 2021
In early 2021, a young boy in Barcelona was the first to receive Pfizer’s investigational gene therapy for Duchenne muscular dystrophy (DMD). This was part of a global Phase 3 human trial to test Pfizer’s lead candidate, PF-06939926, in a cohort of 99 patients with...
by Mark Curtis | Dec 30, 2015
Welcome to your Cell Therapy Deal Review for the month of November. Astellas failed to achieve the majority share it needed to push through a takeover of Ocata Therapeutics valued at $379 million. ImmunoCellular Therapeutics announced a research agreement with MD...
by Mark Curtis | Jan 7, 2014
. Welcome to your Update from the Clinic for the month of December. Athersys and NeoStem both confirm completion of enrollment for phase 2 studies while bluebird bio announces the first patient transplanted in its phase 1/2 study of HGB-205 in patients with...
by Angela C. H. McDonald | Aug 13, 2012
It takes precision, focus and persistence to perfect the art of origami. So perhaps it is no accident that researchers have needed to apply the same skills to overcome challenges in siRNA delivery, right down to the folding. A couple of years ago, my fellow blogger...
by Paul Krzyzanowski | Jul 17, 2012
Faced with patent shortages to replace flagship products, Big Pharma is increasing investments in smaller biotech companies to capture innovations early. Most new companies wither and die if they run out of initial funds before they’re profitable. In biotech,...
Comments